Company: NIVFW
Filing Date: 2025-05-01
Form Type: F-1/A
Source: 0001213900-25-038045
Chunk: 110

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-01
Form: F-1/A
Chunk 110
---
| Effect of foreign currency translation on cash and cash equivalents |     |                    |     44,965 |   |     |      |    (18,962 | ) |
| Cash and cash equivalents, beginning of year                        |     |                    |     54,104 |   |     |      |     27,556 |   |
| Cash and cash equivalents, end of year                              |     |                    |    457,740 |   |     |      |     54,104 |   |

Operating activities Net cash used in operating activities was US$8,264,074 for the year ended December 31, 2024. The difference between NewGenIvf’s net loss of US$474,101 for the year ended December 31, 2024 and the net cash used in operating activities was primarily attributable to (i) an increase of agent’s receivable of US$1,191,795, (ii) a cash deposit of US$1,000,000 with a digital trading platform and settlement of charges in relation to the de-spac and business reorganisation. Net cash used in operating activities was US$1,766,135 for the year ended December 31, 2023. The difference between NewGenIvf’s net profit of US$108,418 for the year ended December 31, 2023 and the net cash used in operating activities was primarily attributable to refund of payment from clients from the contract liabilities and the expenses spent on the legal and professional cost which was capitalized in the book of 2023. 69 Investing activities Net cash used in investing activities in 2024 was US$53,045, primarily representing purchase of plant and equipment. Net cash used in investing activities in 2023 was US$69,848, primarily representing purchase of plant and equipment. Financing activities Net cash provided by financing activities in 2024 was US$8,675,790, primarily representing issuance of share capital utilizing equity line of credit, convertible note issuance and proceeds from issuance of promissory notes all totaling to an amount of $8,583,597. Net cash provided by financing activities in 2023 was US$1,881,493, primarily representing amounts advanced to shareholder and repayment of prior loans from related parties. Contractual Obligations The following table sets forth NewGenIvf’s main contractual obligations and commitments as of December 31, 2024 and December 31, 2023.

|                                     |     | December